FDA Division Director to NCI
Edward Tabor, MD, director of Anti-Infective Drug Products Division, selected as associate director of the National Cancer Institute's biological carcinogenesis program. Tabor will be responsible for all intramural and extramural programs dealing with viral causes of cancer and have a budget of $100 mil. Office of Drug Review II Director James Bilstad, MD, has not yet appointed an acting director for the anti-infective drug division. Tabor will replace Acting Associate Director Richard Adamson, RhD, who is Director of NCI's Division of Cancer Etiology.
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.